At Eton Pharmaceuticals, we develop proprietary formulations of approved molecules in ways that offer improvements for both patients and physicians. These new formulations are superior to existing products. They may be safer or more effective than existing products. They may be less expensive. They may be offered for new indications.

Eton’s pipeline includes multiple innovative 505(b)(2) products. These pipeline candidates are typically reformulations of already FDA-approved molecules, which often translates into shorter development timelines.

Eton is committed to building a diversified pipeline to reduce reliance on any single product in its portfolio. Eton’s philosophy for success is rooted in the pursuit of low-risk, high-value 505(b)(2) product opportunities. Eton evaluates and advances only those opportunities that meet its stringent criteria. Ideal product candidates offer:

Low Clinical Risk
Eton pursues products where existing literature or historic use provide a high degree of certainty in the product’s safety and efficacy.
Low Regulatory Risk
Eton typically meets with the FDA prior to initiating product development to ensure that Eton and the agency agree on an appropriate regulatory pathway.
Low Commercial Risk
Eton pursues products that have already seen commercial demand, including products that are currently compounded or prescribed off-label.

Eton is led by an experienced management team with deep roots in the pharmaceutical industry and a track record of successful value creation. Eton’s management team has completed more than 100 business development transactions, including product and company acquisitions, product licensing deals, partnerships and joint ventures. Eton’s team is focused on achieving aggressive growth through internal product development and high return on investment business development opportunities.

At Eton Pharmaceuticals, we develop proprietary formulations of approved molecules in ways that offer improvements for both patients and physicians. These new formulations are superior to existing products. They may be safer or more effective than existing products. They may be less expensive. They may be offered for new indications.

Eton’s pipeline includes multiple innovative 505(b)(2) products. These pipeline candidates are typically reformulations of already FDA-approved molecules, which often translates into shorter development timelines.

Eton is committed to building a diversified pipeline to reduce reliance on any single product in its portfolio. Eton launched in 2017 with __ products in its pipeline. As of August 2018, Eton has a total of six diverse products in its expanding pipeline.

Eton’s philosophy for success is rooted in the pursuit of low-risk, high-value 505(b)(2) product opportunities. Eton evaluates and advances only those opportunities that meet its stringent criteria. Ideal product candidates offer:

Low Clinical Risk
Eton pursues products where existing literature or historic use provide a high degree of certainty in the product’s safety and efficacy.
Low Regulatory Risk
Eton typically meets with the FDA prior to initiating product development to ensure that Eton and the agency agree on an appropriate regulatory pathway.
Low Commercial Risk
Eton pursues products that have already seen commercial demand, including products that are currently compounded or prescribed off-label.

Eton is led by an experienced management team with deep roots in the pharmaceutical industry and a track record of successful value creation. Eton’s management team has completed more than 100 business development transactions, including product and company acquisitions, product licensing deals, partnerships and joint ventures. Eton’s team is focused on achieving aggressive growth through internal product development and high return on investment business development opportunities.